394 related articles for article (PubMed ID: 26563258)
21. The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine.
Montag G; Stopper H; Ngo QA; Hintzsche H
Curr Cancer Drug Targets; 2019; 19(3):222-230. PubMed ID: 29714145
[TBL] [Abstract][Full Text] [Related]
22. SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition.
Kim JH; Chae M; Choi AR; Sik Kim H; Yoon S
Eur J Pharmacol; 2014 Jan; 723():141-7. PubMed ID: 24333214
[TBL] [Abstract][Full Text] [Related]
23. Antimitotic drugs in cancer chemotherapy: promises and pitfalls.
Marzo I; Naval J
Biochem Pharmacol; 2013 Sep; 86(6):703-10. PubMed ID: 23886991
[TBL] [Abstract][Full Text] [Related]
24. Microtubule S-glutathionylation as a potential approach for antimitotic agents.
Chen W; Seefeldt T; Young A; Zhang X; Zhao Y; Ruffolo J; Kaushik RS; Guan X
BMC Cancer; 2012 Jun; 12():245. PubMed ID: 22703118
[TBL] [Abstract][Full Text] [Related]
25. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.
Levrier C; Sadowski MC; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Nelson CC
Mol Cancer Ther; 2017 Jan; 16(1):3-15. PubMed ID: 27760837
[TBL] [Abstract][Full Text] [Related]
26. Natural products as new antimitotic compounds for anticancer drug development.
Paier CRK; Maranhão SS; Carneiro TR; Lima LM; Rocha DD; Santos RDS; Farias KM; Moraes-Filho MO; Pessoa C
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e813s. PubMed ID: 30540125
[TBL] [Abstract][Full Text] [Related]
27. Targeting microtubules for cancer chemotherapy.
Zhou J; Giannakakou P
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
[TBL] [Abstract][Full Text] [Related]
28. Clinical Development of Anti-mitotic Drugs in Cancer.
Olziersky AM; Labidi-Galy SI
Adv Exp Med Biol; 2017; 1002():125-152. PubMed ID: 28600785
[TBL] [Abstract][Full Text] [Related]
29. A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line.
Mqoco T; Stander A; Engelbrecht AM; Joubert AM
Biomed Res Int; 2019; 2019():1850462. PubMed ID: 31886177
[TBL] [Abstract][Full Text] [Related]
30. Advances in mitotic inhibitors for cancer treatment.
Jiang N; Wang X; Yang Y; Dai W
Mini Rev Med Chem; 2006 Aug; 6(8):885-95. PubMed ID: 16918495
[TBL] [Abstract][Full Text] [Related]
31. Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic.
Shi J; Mitchison TJ
Endocr Relat Cancer; 2017 Sep; 24(9):T83-T96. PubMed ID: 28249963
[TBL] [Abstract][Full Text] [Related]
32. Vinca alkaloids vs. taxanes as therapy in lymphoid malignancies: do our experimental models obscure our understanding of how these drugs really work?
Lerner A; Andrea N
Cancer Invest; 2005; 23(1):100-2. PubMed ID: 15779874
[No Abstract] [Full Text] [Related]
33. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.
Komlodi-Pasztor E; Sackett DL; Fojo AT
Clin Cancer Res; 2012 Jan; 18(1):51-63. PubMed ID: 22215906
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacology and use of microtubule-targeting agents in cancer therapy.
Zelnak AB
Methods Mol Med; 2007; 137():209-34. PubMed ID: 18085232
[TBL] [Abstract][Full Text] [Related]
35. Antimitotic agents of natural origin.
Nagle A; Hur W; Gray NS
Curr Drug Targets; 2006 Mar; 7(3):305-26. PubMed ID: 16515529
[TBL] [Abstract][Full Text] [Related]
36. Tubulin: an example of targeted chemotherapy.
Seligmann J; Twelves C
Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxicity, cell cycle kinetics and morphonuclear-induced effects of Vinca alkaloid anticancer agents.
Pauwels O; Kiss R; Pasteels JL; Atassi G
J Pharm Pharmacol; 1995 Oct; 47(10):870-5. PubMed ID: 8583358
[TBL] [Abstract][Full Text] [Related]
38. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma.
Aneja R; Vangapandu SN; Lopus M; Chandra R; Panda D; Joshi HC
Mol Pharmacol; 2006 Jun; 69(6):1801-9. PubMed ID: 16517755
[TBL] [Abstract][Full Text] [Related]
39. Loss of Aurora Kinase Signaling Allows Lung Cancer Cells to Adopt Endoreplication and Form Polyploid Giant Cancer Cells That Resist Antimitotic Drugs.
Tagal V; Roth MG
Cancer Res; 2021 Jan; 81(2):400-413. PubMed ID: 33172929
[TBL] [Abstract][Full Text] [Related]
40. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
